PL355016A1 - Farmaceutyczne kompozycje zawierające środek fibrynolityczny - Google Patents

Farmaceutyczne kompozycje zawierające środek fibrynolityczny

Info

Publication number
PL355016A1
PL355016A1 PL00355016A PL35501600A PL355016A1 PL 355016 A1 PL355016 A1 PL 355016A1 PL 00355016 A PL00355016 A PL 00355016A PL 35501600 A PL35501600 A PL 35501600A PL 355016 A1 PL355016 A1 PL 355016A1
Authority
PL
Poland
Prior art keywords
pharmaceutical compositions
fibrinolytic agent
lyophilized
agent
lyophilized composition
Prior art date
Application number
PL00355016A
Other languages
English (en)
Inventor
Brent S. Kendrick
Brian Peterson
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of PL355016A1 publication Critical patent/PL355016A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL00355016A 1999-10-01 2000-09-29 Farmaceutyczne kompozycje zawierające środek fibrynolityczny PL355016A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/411,335 US6440414B1 (en) 1999-10-01 1999-10-01 Pharmaceutical compositions of fibrinolytic agent

Publications (1)

Publication Number Publication Date
PL355016A1 true PL355016A1 (pl) 2004-03-22

Family

ID=23628514

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00355016A PL355016A1 (pl) 1999-10-01 2000-09-29 Farmaceutyczne kompozycje zawierające środek fibrynolityczny

Country Status (28)

Country Link
US (4) US6440414B1 (pl)
EP (2) EP1438967A3 (pl)
JP (1) JP2003510369A (pl)
KR (1) KR100717435B1 (pl)
CN (2) CN101209347A (pl)
AT (1) ATE262923T1 (pl)
AU (1) AU769313B2 (pl)
BG (1) BG106578A (pl)
BR (1) BR0014420A (pl)
CA (1) CA2385966A1 (pl)
CZ (1) CZ20021033A3 (pl)
DE (2) DE60009529T2 (pl)
DK (1) DK1220685T3 (pl)
EA (2) EA006600B1 (pl)
ES (2) ES2224917T1 (pl)
HK (1) HK1049112B (pl)
HU (1) HUP0202654A3 (pl)
IL (1) IL148842A0 (pl)
MX (1) MXPA02003197A (pl)
NO (1) NO20021500L (pl)
NZ (4) NZ540967A (pl)
PL (1) PL355016A1 (pl)
PT (1) PT1220685E (pl)
SG (1) SG148823A1 (pl)
SK (1) SK4242002A3 (pl)
WO (1) WO2001024817A2 (pl)
YU (1) YU23302A (pl)
ZA (1) ZA200202400B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2193809E (pt) * 1999-02-22 2015-08-24 Baxter Int Formulações de fator viii livres de albumina
US6261820B1 (en) 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US6455269B1 (en) * 1999-12-17 2002-09-24 Amgen, Inc. Method for localized administration of fibrinolytic metalloproteinases
US7033776B2 (en) 1999-12-17 2006-04-25 Amgen Inc. Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US20050239746A1 (en) * 2002-02-01 2005-10-27 Penkler Lawrence J Pharmaceutical composition
EP1476178A4 (en) * 2002-02-14 2009-08-26 Bayer Pharmaceuticals Corp FORMULATION STRATEGIES IN STABILIZING PEPTIDES IN ORGANIC SOLVENTS AND DRY CONDITIONS
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
MX2007006822A (es) * 2004-12-15 2007-07-24 Amgen Inc Formulaciones terapeuticas para el factor de crecimiento de queratinocitos.
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN101309916A (zh) * 2005-11-18 2008-11-19 卫材R&D管理有限公司 制备肉桂酰胺衍生物的方法
US7867747B2 (en) * 2006-11-08 2011-01-11 Korea Ocean Research And Development Institute Fibrinolytic metalloprotease and composition comprising the same
EP1958618A1 (de) 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
BRPI0921429B1 (pt) * 2008-11-07 2022-07-12 Takeda Pharmaceutical Company Limited Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
US9226953B2 (en) * 2009-07-10 2016-01-05 Thrombogenics Nv Variants of plasminogen and plasmin
CN102000022A (zh) * 2010-11-23 2011-04-06 郑州大学 注射用重组双功能纤溶酶冻干制剂及其制备方法
ES2583082T3 (es) 2011-01-05 2016-09-19 Thrombogenics N.V. Variantes de plasminógeno y plasmina
RU2604810C2 (ru) 2011-08-12 2016-12-10 Тромбодженикс Н.В. Варианты плазминогена и плазмина
US20140212405A1 (en) 2013-01-28 2014-07-31 2294719 Ontario Limited Fibrinolytic/Proteolytic Treatment of Myofacial and Neuropathic Pain and Related Conditions
CN107250375A (zh) * 2014-11-06 2017-10-13 科罗拉多州立大学董事会 在血栓溶解剂存在下使用粘弹性分析鉴定新疾病状态
KR20210113271A (ko) * 2019-01-06 2021-09-15 엔도 글로벌 에스테틱스 리미티드 콜라게나제 제형 및 이의 제조 방법

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2310133A2 (fr) 1975-05-05 1976-12-03 Fabre Sa Pierre Nouveau medicament comportant un activateur du plasminogene perfectionne
EP0062642B1 (en) * 1980-06-27 1986-09-10 Movement Techniques Limited Movement measuring apparatus and landmarks for use therewith
US4447236A (en) * 1982-02-05 1984-05-08 Cordis Corporation Infusion catheter system
US4610879A (en) 1984-01-06 1986-09-09 University Of Southern California Fibrinolytic enzyme from snake vernom
CA1237482A (en) * 1984-03-09 1988-05-31 Frank B. Stiles Catheter for effecting removal of obstructions from a biological duct
US4755167A (en) * 1984-04-10 1988-07-05 Research Corporation In vivo method for distribution and stirring of therapeutic agents
US4885242A (en) * 1984-10-30 1989-12-05 Phillips Petroleum Company Genes from pichia histidine pathway and uses thereof
US4837148A (en) * 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4855231A (en) * 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4818700A (en) * 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4812405A (en) * 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5000185A (en) * 1986-02-28 1991-03-19 Cardiovascular Imaging Systems, Inc. Method for intravascular two-dimensional ultrasonography and recanalization
US4848700A (en) * 1987-04-16 1989-07-18 Lockheed John A Canard control system for aircraft
ZA889415B (en) 1987-12-18 1989-09-27 Chiron Corp Compositions and method for recombinant production of crotalidus venum fibrolase
WO1990007352A1 (en) 1989-01-04 1990-07-12 Boston Scientific Corporation Angioplasty catheter
US5222941A (en) * 1990-01-12 1993-06-29 Don Michael T Anthony Method of dissolving an obstruction in a vessel
DE69133066T2 (de) 1990-01-16 2003-03-06 Centro De Ingenieria Genetica Y Biotecnologia, Cubanacan Playa Verfahren zur Expression heterologischer Gene in der Hefe Pichia Pastoris, Expressionsverfahren und transformierte Mikroorganismen
US5709676A (en) * 1990-02-14 1998-01-20 Alt; Eckhard Synergistic treatment of stenosed blood vessels using shock waves and dissolving medication
US5250034A (en) * 1990-09-17 1993-10-05 E-Z-Em, Inc. Pressure responsive valve catheter
US5167628A (en) * 1991-05-02 1992-12-01 Boyles Paul W Aortic balloon catheter assembly for indirect infusion of the coronary arteries
US5380273A (en) * 1992-05-19 1995-01-10 Dubrul; Will R. Vibrating catheter
EP0624642B1 (en) 1993-05-12 1999-01-20 Indian Council For Medical Research Novel thrombolytic agent, process for preparing same and its use for the preparation of a thrombi dissolving medicament
US5370653A (en) * 1993-07-22 1994-12-06 Micro Therapeutics, Inc. Thrombectomy method and apparatus
EP0689843B1 (en) 1993-12-17 2003-09-10 Mochida Pharmaceutical Co., Ltd. Composition containing soluble thrombomodulins
US5626564A (en) * 1995-03-31 1997-05-06 Creighton University Adjustable sideholes catheter
US5830468A (en) * 1995-05-17 1998-11-03 The New York Blood Center, Inc. Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
US6020181A (en) * 1995-05-17 2000-02-01 New York Blood, Inc. Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
WO1997045105A1 (en) 1996-05-24 1997-12-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
US5951981A (en) 1996-12-02 1999-09-14 Diatide, Inc. Thrombolytic agents with antithrombotic activity
US6413760B1 (en) 1997-04-15 2002-07-02 Genetics Institute, Inc. Highly purified mocarhagin cobra venom protease polynucleotides endcoding same and related proteases and therapeutic uses thereof
US6261820B1 (en) 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US6455269B1 (en) * 1999-12-17 2002-09-24 Amgen, Inc. Method for localized administration of fibrinolytic metalloproteinases
WO2002012283A2 (en) 2000-08-03 2002-02-14 Zymogenetics, Inc. Disintegrin homologs, zsnk10, zsnk11, and zsnk12

Also Published As

Publication number Publication date
NZ530959A (en) 2005-08-26
WO2001024817A2 (en) 2001-04-12
US20060263347A1 (en) 2006-11-23
ZA200202400B (en) 2003-05-28
EA200400182A1 (ru) 2004-08-26
EP1220685A2 (en) 2002-07-10
DE60009529D1 (de) 2004-05-06
YU23302A (sh) 2005-06-10
NO20021500L (no) 2002-05-27
US6440414B1 (en) 2002-08-27
ES2224917T1 (es) 2005-03-16
NZ550200A (en) 2008-04-30
KR20020053065A (ko) 2002-07-04
CN101209347A (zh) 2008-07-02
HK1049112A1 (en) 2003-05-02
ES2218228T3 (es) 2004-11-16
DE04007657T1 (de) 2005-01-13
EA004627B1 (ru) 2004-06-24
CN1402641A (zh) 2003-03-12
BR0014420A (pt) 2002-06-11
MXPA02003197A (es) 2002-09-30
SK4242002A3 (en) 2003-08-05
EP1438967A2 (en) 2004-07-21
DK1220685T3 (da) 2004-08-02
SG148823A1 (en) 2009-01-29
CZ20021033A3 (cs) 2003-06-18
US20020192207A1 (en) 2002-12-19
PT1220685E (pt) 2004-08-31
US20060246053A1 (en) 2006-11-02
US7311908B2 (en) 2007-12-25
HK1049112B (en) 2005-01-21
ATE262923T1 (de) 2004-04-15
KR100717435B1 (ko) 2007-05-14
EP1220685B1 (en) 2004-03-31
JP2003510369A (ja) 2003-03-18
NZ540967A (en) 2007-02-23
HUP0202654A2 (hu) 2002-12-28
NZ518007A (en) 2004-03-26
EA200200396A1 (ru) 2002-10-31
US7138114B2 (en) 2006-11-21
NO20021500D0 (no) 2002-03-26
BG106578A (bg) 2003-04-30
AU7743000A (en) 2001-05-10
CA2385966A1 (en) 2001-04-12
CN100353999C (zh) 2007-12-12
IL148842A0 (en) 2002-09-12
WO2001024817A3 (en) 2001-10-18
DE60009529T2 (de) 2005-04-14
US7244426B2 (en) 2007-07-17
HUP0202654A3 (en) 2003-11-28
EP1438967A3 (en) 2005-01-26
EA006600B1 (ru) 2006-02-24
AU769313B2 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
IL148842A0 (en) Pharmaceutical compositions of fibrinolytic agent
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
YU23102A (sh) Jedinjenja za lečenje ishemije
GB9409778D0 (en) Compositions
IL140710A0 (en) Pulmonary delivery of active agents
IL139862A0 (en) Thiazolidine or pyrrolidine derivatives as dipeptidyl peptidase iv effectors and pharmaceutical compositions containing the same
WO2000007979A3 (en) Compounds and compositions for delivering active agents
ATE270557T1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
IL127581A0 (en) Crystal form i of clarithromycin
HUP0103341A3 (en) Azetidine derivatives, preparation and pharmaceutical compositions thereof
MXPA02002086A (es) Composiciones que contienen metal, preparaciones y usos.
GR1003350B (el) Νεες ενωσεις
AU2496199A (en) Copolymer compositions for oral delivery
GB2367004A (en) Pharmaceutical compositions
WO2000050046A8 (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
IL137911A (en) Pharmaceutical formulation of a didemnin compound
IL140140A0 (en) Thyroid hormone analogues and methods for their preparation
WO1999027892A3 (de) Lagerstabile kationisch polymerisierende zubereitungen mit verbessertem härtungsverhalten
MY121982A (en) Pharmaceutical compositions for freeze drying
IL128500A (en) SUBSTITUTED 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINES AND 2-AMINOCYCLOHEPTA[b] BENZOFURANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BG104827A (en) 3',3'-n-bis-substituted macrolide lhrh antagonists
WO2001022917A3 (en) Effervescent compositions comprising nimesulide
WO2001015777A8 (en) Pulmonary-administration of mineral ascorbates
SI1189600T1 (en) Grf-containing lyophilized pharmaceutical compositions
ZA974476B (en) Systematic method for making shotcrete and the like cementitious compositions and such compositions.

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)